GENEVA
CarthaGenetics® provides consulting services to rare diseases, advanced therapies, and orphan drugs companies who want to step in the complex European markets (including Turkey) and the fast-growing North African markets.
CarthaGenetics® was founded in 2004 by Philippe Carteron, on the basis of his personal commitment to the treatment of orphan diseases (rare
& mostly genetic diseases) across Western Europe, Turkey & North Africa. CarthaGenetics® has worked for the most prestigious biotech and pharma companies, as Alexion, Alnylam, Amicus, Biogen, BioMarin, FoldRX/Pfizer, Genzyme, Horizon, Insmed, Orchard, PTC, RegenXbio, Shire, Ultragenyx, as well as for Turkish Ministry of Health and Turkish Pharmacist Association (TEB).
CarthaGenetics® is focused on innovative medicines, including cell and gene therapies and has 3 main areas of expertise:
1) Speed up the enrollment in Clinical Trial(s) through patient identification in cooperation with CROs:
- Our direct presence in countries with high birth numbers as Turkey, Algeria, Tunisia, Morocco is increasing the chances to complete enrollment in a shorter time.
- Our strong network among Pediatricians, Metabolicians, (Pediatric) Neurologists, Lipidologists, (Pediatric) Nephrologists, Geneticists, Hematologists and Oncologists will speed up patients identification.
2) Early Access Program (EAP or NPP) including Compassionate Use and Named Patient Sales (NPS) in countries where such programs are allowed as for instance
- ATU (autorisations temporaires d'utilisation) in France
- Law 648 / Law 326 in Italy
- Endikasyon D Kullanm Klavuzu in Turkey
3) Biosimilars of Orphan Drugs for North Africa where there is no Orphan Drug exclusivity, representing a population about 100M.
For any question please send us a message on contact@carthagenetics.com or contact us at our Swiss Headquarter +41 22 575 31 31 and visit our website atArray
Pas de formation renseignée
